Bridging the Gap: Index Volume [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

26 catabolism * CD4

12th World AIDS Conference

Keyword

Abstract --

Keyword

Abstract
S as a cause of death in Catalonia (Spain): 1985-1995/Changes i 24190
childbearing women in, Spain: Results from the unlinke 60549
of HIV-1 envelope by its catalytic antibody/Destruction of gp41 of 41190
collaborative model for catalyzing and coordinating a community r 44222
e study/Central venous catheter infections in AIDS patients: Resul 22120
with tunneled Groshong /Infective complications in AIDS p 22451
survey/Central venous catheters (CVC)-related bacteremia in HI 22106
ffected by HIV/AIDS/ Catholic AIDS link response to spiritual an 34188
prevention efforts of US Social Service Agencies/Strengt 34191
cted by HIV/AIDS/The parish as welcoming and healing 60175
mong European and Caucasian heterosexuals/Using condom 33157
opulation: Its relation to Caucasians descendance/Frequency of 13331
n Africans exists also in: Analysis of the HLA-A28 anti 21202
oad levels in a cohort of and African-Americans/MHC 60870
ent of HIV/AIDS, hope, caution and options for resource limited co 42315
the changes in the oral cavity and the oesophagus of HIV patients 32123
tion of HIV-1 in the oral of infected women: Association with 60608
ty based organization ( CBO ) in New York City/Patterns of antiretr 22366
marginalised group, a and a regional university/HIV/AIDS a 93*/43380
y-based organisations ( CBOs )/Taking control-PLWHAs and Austr 34134
ty based organization ( ) leaders/A combined AIDS situatio 34184
y-based organizations ( ) for HIV prevention/Building, sustai 34337
vention approaches to /Bridging the gap between science a 43155
e/CCR5-genotype and CC-chemokine levels are not significantly 13380
mmune responses and receptor 5 (CCR5) genoty 31114
romiscuous usage of CC and CXC chemokine coreceptors in viv 8*/21134
tion and association of chemokine receptor 5 and focal adhesi 55*/21135
ontaining biopolymers ( CCBs ) of bacterial and lymphoid cells/HIV 41204
nts/Protective effect of CCR-5A32 deletion on cerebral or extracer 13184
A32 gene deletion and CCR-5 M303 mutation in South African po 11122
rological parameters in homozygote and A32 heterozygote 13351
hild HIV-1 transmission/ genotype may confer resistance to 11*/21107
HIV infection?/Do A32 deletions protect intravenous drug 23180
te infection and CCR5, CCR1, IFNy, RANTES expression in lymp 11222
/Role of CCR5A32 and CCR2-64i heterozygosities in the pathoge 12110
ers/Combined effect of CCR2, CCR5 and SDF1 chemokine varian 13183
T, CCR5/Accr5, and/or -+/641 genotypes/Longitudinal stu 13353
s/Chemokine receptor CCR2b 641 polymorphism and its relation t 13327
es CCR5, CXCR4, and CCR3 expression/Repertoire of chemokin 335*/21109

ssion in lymphoid cells/ stimulation exerts antiviral effects an
rm surviving IDUs/The subset of CD8 cells predicts progres
herapy/CD45RO+ and CD45RA + cells in HIV-infected children, o
HIV-1 strains that infect CD4 + T-cell lines, Molt4 and SupT1/Study

41234
42191
13364
11111

on: RANTES activity via is required for specific T-cell cytotoxi
erson homozygous for CCR5A32 /Tropism, characterization, and
HIV-1 infection/Role of and CCR2-64i heterozygosities
vidence for a role of the deletion mutation on disease pr
duals heterozygous for /Increased CD4+ T cell respons
/The prevalence of the CCR5- A32 gene deletion and CCR-5 M30
ytes are permissive for, but not for CXCR4-dependent HIV
enotypic expressions of A2/A32 homozygosity/Phenotypic
ing factor concentrate/ CCR5-genotype and CC-chemokine level
nsdominant inhibition of CCR5-mediated HIV-1 infection by ccr5A
AOP-RANTES inhibits CCR5 recycling - A novel inhibitory mecha
on of HIV-1 infection by antagonists/Modulation of HIV-1 inf
e A32 deletion allele of coreceptor gene in HIV infected and
okines receptors (A32 ) sequency codificator in blood donor
rus acute infection and, CCR1, IFNy, RANTES expression i
chemokine receptor 5 ( ) gene in an HIV-1-infected patient/
se progression/Role of chemokine receptor gene in vertical
mbined effect of CCR2, and SDF1 chemokine variants on cli
ean Ashkenazi origin of -A32A32/Evidence from the Australi
NP) carrying either WT, /Accr5, and/or CCR2-+/641 genoty
atally-exposed infants/ genotype and HIV-1 infection in peri
rogesterone increases, CXCR4, and CCR3 expression/Re
mozygous defect in the gene gives a high degree of protecti
chemokine receptor 5 ( ) genotype in long-term survivors of
ars of age: Influence of genotype and antiretroviral treatme
chemokine receptor 5 ( ) genotype in highly exposed but per
-Gal stably expressing suitable for infectivity assay of T- an
rrelates/Prevalence of heterozygous deletion in long-term
1 coreceptor usage and defective allele in mother-to-child tra
iated HIV-1 infection by ccr 5A32/Mechanism of transdominant inh
ing either WT, CCR5/A 5, and/or CCR2-+/641 genotypes/Lon
h virologic outcomes in CCTG 570: A clinical strategy trial of HIV R
eral expansion of CD8+ CD28 - lymphocytes in the blood of SIVma
atment/Expression of and CD38 by CD8+ T cells in HIV inf
phocytes expression of in HIV-1 infected children: Correlatio
xpression of CD69 and antigens in T lymphocytes of HIV-1(
onsequences of loss of in HIV infection/Functional consequ
acutely infected by HIV/ costimulation increases virus replica
new subrogate marker/ /8 Evaluation of a new subrogate mar
ren/The expression of and DR are markers of immune activ
pression of CD28 and by CD8+ T cells in HIV infection corr

31148
11112
12110
13304
22419
11122
13*/21147
22415
13380
54*/11105
58*/11102
56*/11103
11108
11123
11222
12105
12162
13183
13312
13353
215*/13365
335*/21109
23255
31114
31138
31147
41163
60250
60834
54*/11105
13353
32379
11220
116*/31170
31173
31181
60340
60407
12140
213*/31166
116*/31170

ons of gp120 with both
V-1 Nef protein induces
caques correlates with
s monkey lymphocytes/
the prognostic value of
with HIV-1 and HTLV-2/
nversion, 1987 to 1995/
G 175/HIV serum RNA,
elation to viral load, and
trovirals/HIV-RNA and
on to clinical AIDS after
n Yaounde, Cameroon/
9, CD25, HLA-DR and
udine-resistant strain/
iral naive subjects with
burden reductions and
ly treated patients with
i adult population with
children/Viral load and
aive patients with >500
treatment/Changes in
w-up of antigen-specific
/Correlations between
unts as an alternative to
IDS: QASI program for
th AIDS diagnosis by a
A plasma viral load and
on to HIV infection and
angkok/Viral load and
le factory cohort/Serial
al therapy (HAART) on
n injection drug users/
hism and its relation to
1 plasma viral load and
on the role of heroin on
sitive patients with <50
HIV-1 infection/Limited
on/Perturbations in the
reased turnover of both
dividuals/HIV infected
cosal versus circulating
or proliferation in blood
n-progression (LT-NP)/
cal adhesion kinase in
pe interactions with the
ect of HIV-1 infection on
CD8 T cells induced by
s the major inducer of
mediated apoptosis of
s in HIV-gpl20-treated
gus monkeys with rapid
ar cytokine synthesis in
V-infected patients with
d individuals with stable
between HIV viral load,
A copies in plasma and
f reservoir of HIV-1 in
erapy on viral load and
s in naive patients with
ents with less than 200
apy in patients with low
r CCR5A32/Increased
DU) after accounting for
rsons/Depression and
ositively correlate with
eceptor expression in
evidence for increased
ergy and dysfunction of
ates with viral load and
gression/Alterations of
nomic neuropathy and
a in AIDS patients with
Midlands, UK/Idiopathic
udy (MACS)/HIV RNA,
mplant/Significance of

Georgia/Viral load and

and V3 loop binding proteins/The bin 11114
+ T-cell apoptosis through functional u 11145
depletion and is associated with T-cell 11220
/GP120mac251 and phospholipase A 11230
cell counts: The EuroSIDA study/Imp 12106
+ lymphocyte counts and HIV disease 12113
+ response within 6 months after HIV s 12119
cell numbers and risk for clinical endp 507*/12124
+ T-cell count/The role of HIV-1 pheno 12126
+ decline without therapy: Reference v 12127
+ cell count falls below 200/gl/Predicti 12133
+, CD8+ cell counts, CD4/CD8 ratio an 12138
5RO expression, Interleukin-2 synthe 12180
and CD8 response within one year aft 12184
+ counts >400 cells//l and viral load 286*/12204
increases in HIV-1 infected patients w 129*/12219
below 50/mm3 (Italian ISS-IP1 Study 132*/12237
counts 150-350/mm3 and predomina 12241
-cell count under a triple-therapy with 12256
cells/mm3/lndinavir (IDV) in combinat 12311
+ cell count and the risk of opportunisti 12331
cell function in HAART patients/Folio 12341
and RNA response in antiretroviral-na 12363
counts in resource poor countries/Tot 12426
testing/International program for qual 13101
count of <200 cells/[L/AIDS diagnos 13214
counts before and after anti-tuberculo 13271
+ cell count in peripheral blood/HPV D 13293
cell count in injecting drug users (IDU 191*/13302
counts following HIV seroconversion i 13316
lymphocyte counts in France/Impact 13318
cell count and viral load in HTLV-II an 13326
T-cell counts and disease progressio 13327
counts in surviving and non-surviving 13329
+ decline in injecting drug users/New 13334
count/Impact of indinavir with zidovud 14339
+ T-cell renewal as a mechanism for C 270*/21103
+ TCR VI repertoire indicate fast prog 21104
and CD8 T-cells in HIV-1 infection unti 268*/21108
+ syncytia are commonly found in the 21111
+ T cells in seronegative controls/Incr 21119
+ T cells during HIV infection and treat 21121
Thl cells specific for HIV-1 antigens a 21126
+ T cells by macrophage-tropic HIV en 55*/21135
/CXCR4 receptor complex/Signal tran 21140
5 phosphatase activity/The effect of H 21151
crosslinking (XL) of CD4 T cells/Indir 274*/21159
+ T cell death in HIV-1-infected subjec 21160
T cells from HIV+ patients is proportio 21165
+ T cells/Either mithocondrial damage 21166
+ lymphopenia/Analysis of Fas/FasL i 21167
+ and CD8+ cell subsets during progre 217*/21171
below 50/zl/Tuberculosis (TB) in HIV 22128
cell count above 200//zL/Withdrawal 22179
level and cervicovaginal human papill 22313
counts to human papillomavirus (HPV 22317
cells in infants and children receiving 22358
count in HIV infected children <36 mo 22364
+ T cells counts from 200 to 500/zl an 22383
/mm3/AZT + 3TC + indinavir vs d4T + 22403
cell counts/Antiretroviral combination 22408
+ T cell response to IL-2 therapy in HIV 22419
+ count and viral load in women/HIV-r 23456
cell count as predictors of quality of lif 24223
+T lymphocyte counts and T cell functi 31109
+ tetanus toxoid specific T cells/Effect 31141
+ T-cell production in HIV-1 infection/ 271*/31168
+ and Vy2VA2+ lymphocytes associa 31169
+T cell number at baseline and during 116*"/31170
5 isoforms expression in paediatric HI 31176
count/Sexual dysfunction in patients 32125
cells count below 50 treated with com 32149
+ T-cell lymphocytopenia (ICL): Experi 32151
+ cell count, and immune activation m 506*/32167
cell count and HIV viral load on CMV r 32243

+ outcome following genotypic antiretr 32291